AI assistant
ONCIMMUNE HOLDINGS PLC Share Issue/Capital Change 2021
7820_sha_2021-09-15_6dcfa1ff-1428-4fbe-aa8f-ce675bc8a4e9.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 8682L
Oncimmune Holdings PLC
15 September 2021
15 September 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Block Listing Six Monthly Return
Oncimmune makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements in respect of Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans (the "Share Option Plans").
| Name of applicant: | Oncimmune Holdings plc |
| Name of scheme: | Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans |
| Period of return: | 16 March 2021 to 15 September 2021 |
| Balance of unallotted securities under scheme(s) from previous return: | 5,830,154 |
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 |
| Less: Number of securities issued/allotted under scheme(s) during period: | 24,409 |
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 5,805,745 |
For further information:
Oncimmune Holdings plc
Ron Kirschner, Company Secretary
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, James Hornigold
+44 (0)20 3829 5000
Singer Capital Markets (Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes, Nigel Birks
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
+44 (0)20 3727 1000
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLRDKPBKKBKDOCD